Movement Alert｜Illumina Rises 5.15% in Regular Trading, Boosted by UBS Upgrade and Imminent S&P 500 Inclusion

Market Focus09-17 22:02

On September 17, Illumina rose 5.15% in regular trading, trading at $241.335 per share with turnover of approximately $99.53 million, extending a multi-day rally driven by a confluence of bullish catalysts.

On the news front, UBS recently upgraded Illumina from Neutral to Buy, lifting its price target from $135 to $260, significantly above the analyst consensus target of $193.61, sending a strong bullish signal. Concurrently, S&P Dow Jones Indices announced that Illumina will be officially added to the S&P 500 index before the open on September 21 as part of its quarterly rebalance, replacing Builders FirstSource. The impending inclusion is expected to generate substantial forced buying from passive index-tracking funds and ETFs, providing additional upside support. RBC Capital Markets has also noted that Illumina's clinical sequencing revenue could sustain mid-teens growth, driven by oncology volume expansion and easing pricing headwinds, while competitive concerns are fading. RBC maintains an Outperform rating with a $230 price target.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1119476952?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-17 22:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1119476952","market":"us","top_or_hot":-1,"title":"Movement Alert｜Illumina Rises 5.15% in Regular Trading, Boosted by UBS Upgrade and Imminent S&P 500 Inclusion","media":"Market Focus","content":"<p><p>On September 17, Illumina rose 5.15% in regular trading, trading at $241.335 per share with turnover of approximately $99.53 million, extending a multi-day rally driven by a confluence of bullish catalysts.</p><p>On the news front, UBS recently upgraded Illumina from Neutral to Buy, lifting its price target from $135 to $260, significantly above the analyst consensus target of $193.61, sending a strong bullish signal. Concurrently, S&P Dow Jones Indices announced that Illumina will be officially added to the S&P 500 index before the open on September 21 as part of its quarterly rebalance, replacing Builders FirstSource. The impending inclusion is expected to generate substantial forced buying from passive index-tracking funds and ETFs, providing additional upside support. RBC Capital Markets has also noted that Illumina's clinical sequencing revenue could sustain mid-teens growth, driven by oncology volume expansion and easing pricing headwinds, while competitive concerns are fading. RBC maintains an Outperform rating with a $230 price target.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Illumina Rises 5.15% in Regular Trading, Boosted by UBS Upgrade and Imminent S&P 500 Inclusion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Illumina Rises 5.15% in Regular Trading, Boosted by UBS Upgrade and Imminent S&P 500 Inclusion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-17 22:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 17, Illumina rose 5.15% in regular trading, trading at $241.335 per share with turnover of approximately $99.53 million, extending a multi-day rally driven by a confluence of bullish catalysts.</p><p>On the news front, UBS recently upgraded Illumina from Neutral to Buy, lifting its price target from $135 to $260, significantly above the analyst consensus target of $193.61, sending a strong bullish signal. Concurrently, S&P Dow Jones Indices announced that Illumina will be officially added to the S&P 500 index before the open on September 21 as part of its quarterly rebalance, replacing Builders FirstSource. The impending inclusion is expected to generate substantial forced buying from passive index-tracking funds and ETFs, providing additional upside support. RBC Capital Markets has also noted that Illumina's clinical sequencing revenue could sustain mid-teens growth, driven by oncology volume expansion and easing pricing headwinds, while competitive concerns are fading. RBC maintains an Outperform rating with a $230 price target.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ILMN","symbol_name":"Illumina","start_time":0,"source_url":"","article_id":"1119476952","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1119476952","pubTimestamp":1789653775,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 17, Illumina rose 5.15% in regular trading, trading at $241.335 per share with turnover of approximately $99.53 million, extending a multi-day rally driven by a confluence of bullish...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ILMN":"Illumina"},"translate_title":"走势警报|Illumina 在瑞银升级和即将纳入标普500的推动下，常规交易中上涨 5.15%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ILMN":1},"content_text":"On September 17, Illumina rose 5.15% in regular trading, trading at $241.335 per share with turnover of approximately $99.53 million, extending a multi-day rally driven by a confluence of bullish catalysts.On the news front, UBS recently upgraded Illumina from Neutral to Buy, lifting its price target from $135 to $260, significantly above the analyst consensus target of $193.61, sending a strong bullish signal. Concurrently, S&P Dow Jones Indices announced that Illumina will be officially added to the S&P 500 index before the open on September 21 as part of its quarterly rebalance, replacing Builders FirstSource. The impending inclusion is expected to generate substantial forced buying from passive index-tracking funds and ETFs, providing additional upside support. RBC Capital Markets has also noted that Illumina's clinical sequencing revenue could sustain mid-teens growth, driven by oncology volume expansion and easing pricing headwinds, while competitive concerns are fading. RBC maintains an Outperform rating with a $230 price target.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1119476952","isCrawlerRequest":true}